Clinical pharmacokinetics and metabolism of irinotecan (CPT-11).
Ron H.J. Mathijssen(Erasmus MC), Alex Sparreboom(The Ohio State University)
PubMed
August 1, 2001
Cited by 752
Related Papers
Cremophor EL
|European Journal of Cancer|2001|1.6k
DPYD genotype-guided dose individualisation of fluoropyrimidine therapy in patients with cancer: a prospective safety analysis
|The Lancet Oncology|2018|419
Phase I clinical trial of oral 2-methoxyestradiol, an antiangiogenic and apoptotic agent, in patients with solid tumors
|Cancer Biology & Therapy|2006|155
Therapeutic Drug Monitoring in Oncology: International Association of Therapeutic Drug Monitoring and Clinical Toxicology Recommendations for 5‐Fluorouracil Therapy
|Clinical Pharmacology & Therapeutics|2018|126
Characterization of in vitro and in vivo metabolic pathways of the investigational anticancer agent, 2‐methoxyestradiol
|Journal of Pharmaceutical Sciences|2007|38